Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study
- 1 July 2017
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 134, 185-206
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81373282, 21302111)
- National High-tech R&D Program of China (2014AA020523)
- Major Project of Science and Technology of Shandong Province (2015ZDJS04001)
- Young Scholars Program of Shandong University (2016 WLI H33)
- National Institutes of Health/National Cancer Institute (CA163452 to C.J.C.)
This publication has 21 references indexed in Scilit:
- Inside HDACs with more selective HDAC inhibitorsEuropean Journal of Medicinal Chemistry, 2016
- HDAC expression and activity is upregulated in diseased lupus-prone miceInternational Immunopharmacology, 2015
- HDAC inhibitor misprocesses bantam oncomiRNA, but stimulates hid induced apoptotic pathwayScientific Reports, 2015
- 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 BromodomainACS Medicinal Chemistry Letters, 2014
- HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levelsProceedings of the National Academy of Sciences of the United States of America, 2014
- Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And PerspectivesFuture Medicinal Chemistry, 2012
- Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's diseaseNeurobiology of Disease, 2012
- HDAC1 regulates pluripotency and lineage specific transcriptional networks in embryonic and trophoblast stem cellsNucleic Acids Research, 2011
- Epigenetics and cancer treatmentEuropean Journal of Pharmacology, 2009
- HDAC2: a critical factor in health and diseaseTrends in Pharmacological Sciences, 2009